Navigation Links
Savient Pharmaceuticals Announces Acceptance of Two Gout-Related,Abstracts for Poster Presentation at the European League Against,Rheumatism (EULAR) 2007 Annual Congress

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Jun 6, 2007 - Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that two abstracts exploring Phase 2 Puricase(R) (PEG-uricase) data and quality of life in treatment-failure gout patients will be presented at the European League Against Rheumatism (EULAR) 2007 Annual Congress taking place June 13 - 16th in Barcelona, Spain. Puricase is a PEGylated recombinant porcine urate oxidase currently in Phase 3 development for patients with treatment-failure gout.

The abstracts selected for poster presentation on Thursday, June 14 are:

-- "Pharmacokinetics and Pharmacodynamics of PEG-uricase in Patients with Hyperuricemia and Treatment-Failure Gout" (abstract #THU0358)

-- "Validation of the SF-36 and HAQ-DI in Patients with Treatment-Failure Gout" (abstract #THU0359)

The first poster presents pharmacokinetic and pharmacodynamic data from the 41-patient, 3-month duration, open-label Phase 2 trial of Puricase. The second poster presents an analysis of the application of instruments for measuring health-related quality of life and physical functioning to the assessment of patient-reported outcomes in treatment-failure gout (defined as gout patients for whom allopurinol is contraindicated or is ineffective).

In addition to the two abstracts accepted for poster presentation, two additional abstracts have been accepted for publication on-line. These are:

-- Weekly Flare Burden Index: A New Metric for Evaluating Gout Treatment (abstract # AB0748)

-- Uric Acid Lowering Therapy for Gout: Patterns of Care (abstract # AB0745)

For information about the EULAR scientific program, please visit the Congress website at www.eular.org

Savient licensed exclusive, worldwide rights to the technologies related to Puricase from Duke University ("Duke") of North Carolina and Mountain View Pharmaceuticals, Inc. ("MVP"), a California corporatio
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:11/23/2014)...  Aurobindo Pharma USA is ... mg 100-count bottles to the consumer level. The product ... Empty capsules could result in missed dose(s) ... range from no effect, short term reduction in efficacy, ... seizures) that could be life-threatening. Aurobindo Pharma ...
(Date:11/22/2014)... MIAMI , Nov. 22, 2014  New data ... for the most common form of female sexual dysfunction, ... cognitive function or driving performance in premenopausal women when ... Sexual Medicine Society of North America,s ... Miami . SMSNA accepted ...
(Date:11/22/2014)... noviembre de 2014  BioClinica®, Inc., un proveedor ... tecnologías eClinical, ha indicado un aumento de la ... el seguimiento basado en el riesgo en los ... del seguimiento basado en el riesgo más allá ... seguimiento o cambio de los métodos de seguimiento. ...
Breaking Medicine Technology:Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
... June 1, 2011 Esperance ... of a $7.5 million Series B financing. Proceeds from ... EP-100, the lead cancer-targeting drug candidate from Esperance,s Cationic ... of the Company,s pipeline. Sanofi led the Series B ...
... June 1, 2011 MMRGlobal, Inc. (OTCBB: ... www.deutsch-boerse.com ) have entered into an agreement ... health IT products and services, including MMRPro for healthcare ... Health Record (PHR) ( www.mmrvideos.com ), on the ...
Cached Medicine Technology:Esperance Pharmaceuticals Completes $7.5 Million Series B Financing 2VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 2VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 3VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 4VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 5
(Date:11/24/2014)... California (PRWEB) November 24, 2014 ... USD 6.19 billion by 2020, according to a ... incidence rates of cardiac arrhythmias clubbed with growing ... of this market. Though still in the budding ... significant rise in usage rates in the recent ...
(Date:11/24/2014)... CHICAGO (PRWEB) November 24, 2014 ... VolparaAnalytics version 1.2 at the 100th Annual Meeting ... November 30-December 5, 2014 (RSNA Booth 1752 – ... version of VolparaAnalytics and the rest of its ... VolparaDensity and VolparaDoseRT, which enable personalized measurements of ...
(Date:11/24/2014)... Virginia (PRWEB) November 24, 2014 Residents ... center stage in this year’s SENIORS GOT TALENT, an ... Guide. , From piano players to classic crooners, to ... clear that older adults are indeed living young. , ... competition because there’s a cash prize, has always been ...
(Date:11/24/2014)... Olaparib functions as a chemical of ... one of the first PARP inhibitors. Sufferers with BRCA1/2 ... of melanoma, and are often immune to other types ... malignancies a exclusive weaknesses, as the tissues of melanoma ... and allow them to proceed splitting. This implies that ...
(Date:11/24/2014)... York (PRWEB) November 24, 2014 The ... by the Family and Children's Association to ... as soap, shampoo, mouthwash and other such items.The Association's ... who are home bound, living in nursing homes, assisted ... to greatly enhance the well being of seniors throughout ...
Breaking Medicine News(10 mins):Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3
... the latest study by the Mayo clinic, injecting an anesthetic ... ,The new study that is being presented today ... the American Urological Association, in San Diego, had found that ... of pain during their biopsy. It was explained that the ...
... disease of the rich and comfortably off in India has now ... classes in India.// , The disease has become so ... with the diabetic population in the country reaching a count of ... to more than double. ,International attention has been drawn ...
... caused drastic increase in cancer among kids across Europe. They ... cases of cancer in kids identified between 1978 and 1997 ... to the results, there was an increase by an average ... in children under the age of 14. ,Majority ...
... According to a review that was published in the Friday’s issue ... reduce their risk of fractures in the later years.// ... got by the age of 18 years. Hence, it is expected ... effects of age-related bone loss and osteoporosis. ,The results ...
... used to treat migraine headaches can be effective in ... zolmitriptan targets nerves that carry pain signals, Dr. Peter ... said.// ,Cluster headaches are not as common as ... 92 patients with cluster headaches. In the final analysis ...
... wells near the Queen’s Balmoral Castle in Scotland kills cancer ... biochemistry at the University of Maribor in Slovenia said that ... and compared them to those placed in normal lab water. ... of colon cancer cells 62.5 percent more quickly than normal ...
Cached Medicine News:Health News:India’s Silent Killer on the Prow 2Health News:17 percent rise in childhood cancer cases due to modern lifestyles 2
CTAD tubes contain theophylline, adenosine and dipyridamol. Coagulation and DTAD tubes are for examination of coagulation parameters....
... tubes contain a buffered sodium ... with a citrate concentration of ... mol/l (3.8%). The mixing ratio ... to 9 parts blood. In ...
Inquire...
Inquire...
Medicine Products: